Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immune checkpoint inhibitor rechallenge in patients with immune-related myositis.

× No keyword cloud information.

9 in total

1. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.

Authors: Sandhya Manohar; Ranine Ghamrawi; Madhuri Chengappa; Busra N Bacik Goksu; Lisa Kottschade; Heidi Finnes; Roxana Dronca; Konstantinos Leventakos; Joerg Herrmann; Sandra M Herrmann
Journal: Kidney360 Date: 2020-01-07

Review 2. Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.

Authors: M Villagrán-García; R Velasco
Journal: Neurol Sci Date: 2022-02-17 Impact factor: 3.830

Review 3. Secondary Causes of Myositis.

Authors: Sarah H Berth; Thomas E Lloyd
Journal: Curr Treat Options Neurol Date: 2020-10-06 Impact factor: 3.598

4. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.

Authors: Luca Diamanti; Alberto Picca; Paola Bini; Matteo Gastaldi; Enrico Alfonsi; Anna Pichiecchio; Eugenia Rota; Roberta Rudà; Francesco Bruno; Veronica Villani; Edvina Galiè; Alberto Vogrig; Mariarosaria Valente; Marco Zoccarato; Valentina Poretto; Bruno Giometto; Carolina Cimminiello; Michele Del Vecchio; Enrico Marchioni
Journal: Neurol Sci Date: 2021-08-23 Impact factor: 3.307

Immune checkpoint inhibitor rechallenge in patients with immune-related myositis.

1. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.

Review 2. Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.

Review 3. Secondary Causes of Myositis.

4. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.

Review 5. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.

6. Pembrolizumab on pre-existing inclusion body myositis: a case report.

7. Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?

8. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.

Review 9. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].